Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
50.91
+0.79 (+1.58%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
63
64
Next >
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
April 22, 2024
From
Bristol Myers Squibb
Via
Business Wire
3 High-Yielding Dividend Stocks That Are Trading at Dirt-Cheap Valuations
April 20, 2024
These stocks pay between 3.2% and 6.7% in dividends.
Via
The Motley Fool
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
April 19, 2024
Via
Benzinga
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
April 19, 2024
Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game.
Via
InvestorPlace
Market Whales and Their Recent Bets on BMY Options
April 15, 2024
Via
Benzinga
Peering Into Bristol-Myers Squibb's Recent Short Interest
April 12, 2024
Via
Benzinga
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
April 21, 2024
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1.
Via
Benzinga
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
April 19, 2024
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel
Via
Benzinga
Exposures
Product Safety
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
April 19, 2024
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk.
Via
The Motley Fool
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
April 18, 2024
Via
AB Newswire
Topics
Economy
Exposures
Interest Rates
3 Undervalued Dividend Stocks to Buy Now to Beat the S&P 500
April 17, 2024
If you want to outperform the S&P 500, consider these undervalued dividend stocks for juicy yields and high total return potential.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
April 17, 2024
These income stocks look like good options at current levels.
Via
The Motley Fool
This Is What Whales Are Betting On Bristol-Myers Squibb
April 11, 2024
Via
Benzinga
3 Pharma Stocks That Are Money-Printing Machines in 2024
April 15, 2024
The economy, and pharma industry, are projected to grow massively. You should invest in these top three pharma stocks.
Via
InvestorPlace
Topics
Economy
Exposures
Economy
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
April 15, 2024
The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect.
Via
Investor's Business Daily
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
April 15, 2024
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF?
Via
The Motley Fool
Topics
Stocks
Exposures
US Equities
Better Growth Play: Merck or The Vanguard Growth Index Fund?
April 15, 2024
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?
Via
The Motley Fool
Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom
April 12, 2024
The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity.
Via
Benzinga
Wall Street Favorites: 3 Warren Buffett Stocks With Strong Buy Ratings for April 2024
April 12, 2024
If you’re wondering where to invest in a stock picker's market, these three Warren Buffett stocks are a good place to start.
Via
InvestorPlace
If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names
April 11, 2024
Capitalize on the biotech sector's boom with these three top biotech stocks to buy, driven by aging demographics and advanced treatments.
Via
InvestorPlace
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
April 11, 2024
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
Via
InvestorPlace
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
April 10, 2024
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE:
Via
Benzinga
2 High-Yield Dividend Stocks Billionaires Are Buying Hand Over Fist
April 10, 2024
These reliable dividend payers offer yields of 3.3% and better at recent prices.
Via
The Motley Fool
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
April 09, 2024
Income-seeking investors can look forward to steady payout raises from these pharma stocks.
Via
The Motley Fool
Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation
April 08, 2024
Bristol Myers Squibb's latest data on Krazati (adagrasib) in combination with cetuximab for KRASG12C-mutated colorectal cancer. Promising objective response rates and progression-free survival. FDA...
Via
Benzinga
Exposures
Product Safety
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
April 08, 2024
From
Bristol Myers Squibb
Via
Business Wire
Bristol Myers' $14B Bet On Schizophrenia - Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other Antipsychotics
April 08, 2024
Interim data from Bristol Myers Squibb's Phase 3 EMERGENT program on KarXT's safety, tolerability, and metabolic outcomes in adults with schizophrenia. Find out how KarXT demonstrated favorable impacts...
Via
Benzinga
Down 75%. Is Agenus Stock a Buy on the Dip?
April 08, 2024
Wall Street analysts who watch the cancer drug developer closely think it could rocket higher.
Via
The Motley Fool
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
April 06, 2024
ProfoundBio will be acquired by Copenhagen’s Genmab A/S in a $1.8 billion all-cash deal. The acquisition will expand Genmab’s drug portfolio, including three ProfoundBio clinical stage ADC candidates...
Via
Talk Markets
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
April 06, 2024
From
Bristol Myers Squibb
Via
Business Wire
< Previous
1
2
...
6
7
8
9
10
11
12
13
14
...
63
64
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.